Post-radioiodine Graves' management: the PRAGMA study

Perros, Petros, Basu, Ansu, Boelaert, Kristien, Dayan, Colin ORCID: https://orcid.org/0000-0002-6557-3462, Vaidya, Bijay, Williams, Graham, Lazarus, John H., Hickey, Janis, Drake, William M., Crown, Anna, Orme, Stephen M., Johnson, Andrew, Ray, David W., Leese, Graham P., Jones, Thomas Hugh, Abraham, Prakash, Grossman, Ashley, Rees, D. Aled ORCID: https://orcid.org/0000-0002-1165-9092, Razvi, Salaman, Gibb, Fraser W., Moran, Carla, Madathil, Asgar, Zarkovic, Milos P., Plummer, Zoe, Jarvis, Sheba, Falinska, Agnieszka, Velusamy, Anand, Sanderson, Violet, Pariani, Nadia, Atkin, Stephen L., Syed, Akheel A., Sathyaoalan, Thozhukat, Nag, Sath, Gilbert, Jackie, Gleeson, Helena, Levy, Miles J., Johnston, Colin, Sturrock, Nigel, Bennett, Stuart, Mishra, Biswa, Malik, Isha and Karavitarki, Niki 2022. Post-radioiodine Graves' management: the PRAGMA study. Clinical Endocrinology 97 (5) , pp. 664-675. 10.1111/cen.14719

PDF - Accepted Post-Print Version Download (852kB)

Abstract

Objective Thyroid status in the months following radioiodine treatment for Graves’ disease can be unstable.Our objective was to quantify frequency of abnormal thyroid function post-radioiodine and compare effectiveness of common management strategies. Design Retrospective, multi-centre, observational study. Patients Adult patients with Graves’ disease treated with radioiodine with 12 months’ follow-up. Measurements Euthyroidism was defined as both serum thyrotropin (TSH) and free thyroxine (FT4) within their reference ranges or, when only one was available, it was within its reference range; hypothyroidism as TSH ≥ 10 mu/L, or subnormal FT4 regardless of TSH; hyperthyroidism as TSH below and FT4 above their reference ranges; dysthyroidism as the sum of hypo- and hyperthyroidism; subclinical hypothyroidism as normal FT4 and TSH between the upper limit of normal and <10 mu/L; subclinical hyperthyroidism as low TSH and normal FT4 Results Of 812 patients studied post-radioiodine, hypothyroidism occurred in 80.7% and hyperthyroidism in 48.6% of patients. Three principal post-radioiodine management strategies were employed: (a) anti-thyroid drugs alone, (b) levothyroxine alone and (c) combination of the two. Differences among these were small. Adherence to national guidelines regarding monitoring thyroid function in the first 6 months was low (21.4–28.7%). No negative outcomes (new-onset/exacerbation of Graves’ orbitopathy, weight gain, cardiovascular events), were associated with dysthyroidism. There were significant differences in demographics, clinical practice, and thyroid status post-radioiodine between centres. Conclusions Dysthyroidism in the 12 months post-radioiodine was common. Differences between post-radioiodine strategies were small, suggesting these interventions alone are unlikely to address the high frequency of dysthyroidism.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine Neuroscience and Mental Health Research Institute (NMHRI) MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG)
Publisher:	Society for Endocrinology
ISSN:	0300-0664
Date of First Compliant Deposit:	11 January 2022
Date of Acceptance:	5 January 2022
Last Modified:	15 Nov 2024 15:45
URI:	https://orca.cardiff.ac.uk/id/eprint/146461

Actions (repository staff only)

Edit Item